<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04058327</url>
  </required_header>
  <id_info>
    <org_study_id>MHE study</org_study_id>
    <nct_id>NCT04058327</nct_id>
  </id_info>
  <brief_title>A Study of MHE in Patients With Liver Diseases</brief_title>
  <official_title>A Study on Early Diagnosis and Treatments of Minimal Hepatic Encephalopathy(MHE) in Patients With Liver Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qin Ning</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tongji Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators analyze the diagnostic efficacy of blood ammonia,
      neurophysiological/psychological tests and blood markers on MHE; to see the progression of HE
      under the condition of the drugs intervention and no drugs intervention in clinical real
      world.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In China, hepatic encephalopathy (HE) is a common complication and one of the most serious
      manifestations of liver disease, not only increasing the risks of death, but also seriously
      affecting the lives of the patients and their caregivers. CHE includes the 1st stage of HE
      and minimal encephalopathy (MHE). It has indicated in a study that the mortality rates of
      covert hepatic encephalopathy (CHE) and overt hepatic encephalopathy (OHE) were both high
      (21% and 21.8% respectively). At present, CHE, especially MHE, is not easy to diagnose in
      daily clinical work. This study aims to early diagnose MHE and find suitable treatment to
      benefit patients. The investigators analyze the diagnostic efficacy of blood ammonia,
      neurophysiological/psychological tests and blood markers on MHE; to see the progression of HE
      under the condition of the drugs intervention and no drugs intervention in clinical real
      world.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>progression of HE</measure>
    <time_frame>1 year</time_frame>
    <description>Incidence of HE progression (none HE, 1 HE, 2/3/4 HE)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>mortality at 90 days</measure>
    <time_frame>90 days</time_frame>
    <description>mortality rate at 90 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>liver disease progression</measure>
    <time_frame>1 year</time_frame>
    <description>Incidence of liver disease progression (such as cirrhosis, decompensation of liver function, liver cancer, liver transplantation, or liver related death)</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Hepatic Encephalopathy</condition>
  <condition>Liver Diseases</condition>
  <condition>Minimal Hepatic Encephalopathy</condition>
  <condition>Cirrhosis, Liver</condition>
  <condition>Acute-On-Chronic Liver Failure</condition>
  <arm_group>
    <arm_group_label>MHE group</arm_group_label>
    <description>Patients whose MHE test are positive</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no HE group</arm_group_label>
    <description>Patients whose MHE test are negative</description>
  </arm_group>
  <arm_group>
    <arm_group_label>overt HE group</arm_group_label>
    <description>2/3/4 HE patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>blood ammonia test, neurophysiological/psychological tests, blood markers.</intervention_name>
    <description>Let the patients do neuropsychological/psychological tests and use blood test for ammonia and blood markers.</description>
    <arm_group_label>MHE group</arm_group_label>
    <arm_group_label>no HE group</arm_group_label>
    <arm_group_label>overt HE group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HE drug treatments in clinical real world</intervention_name>
    <description>record the HE drug treatments in clinical real world if doctors use them</description>
    <arm_group_label>MHE group</arm_group_label>
    <arm_group_label>overt HE group</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum and plasma will be restored in central lab
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with cirrhosis, acute on chronic liver failure or severe liver diseases
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt;18 years old

          -  cirrhosis

          -  acute on chronic liver failure

          -  severe liver diseases

        Exclusion Criteria:

          -  liver cancer

          -  other malignancy

          -  poor eyesight

          -  uncooperative
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qin Ning, MD., PhD.</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Infectious Disease, Tongji Hospital, Tongji Medical College, HUST</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qin Ning, MD., PhD.</last_name>
    <phone>+8602783662391</phone>
    <email>qning@vip.sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qiuyu Cheng, Bachelor</last_name>
    <phone>+8618202761557</phone>
    <email>1226271272@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Infectious Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qin Ning, PHD,MD</last_name>
      <phone>+8602783662391</phone>
      <email>qning@vip.sina.com</email>
    </contact>
    <contact_backup>
      <last_name>Qiuyu Cheng, Bachelor</last_name>
      <phone>+8618202761557</phone>
      <email>1226271272@qq.com</email>
    </contact_backup>
    <investigator>
      <last_name>Qin Ning, PHD,MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tao Chen, PHD,MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Qiuyu Cheng, Bachelor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 11, 2019</study_first_submitted>
  <study_first_submitted_qc>August 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2019</study_first_posted>
  <last_update_submitted>August 13, 2019</last_update_submitted>
  <last_update_submitted_qc>August 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Tongji Hospital</investigator_affiliation>
    <investigator_full_name>Qin Ning</investigator_full_name>
    <investigator_title>Director of Department of Infectious Diseases</investigator_title>
  </responsible_party>
  <keyword>neurophysiological/psychological tests</keyword>
  <keyword>blood ammonia</keyword>
  <keyword>early Diagnosis</keyword>
  <keyword>Minimal Hepatic Encephalopathy</keyword>
  <keyword>Hepatic Encephalopathy</keyword>
  <keyword>Liver Diseases</keyword>
  <keyword>Cirrhosis, Liver</keyword>
  <keyword>Acute-On-Chronic Liver Failure</keyword>
  <keyword>early treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Hepatic Insufficiency</mesh_term>
    <mesh_term>Hepatic Encephalopathy</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
    <mesh_term>Acute-On-Chronic Liver Failure</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

